Authors:
MARSHALL DA
SIMPSON KN
MCHUTCHINSON J
MARTINOT M
PAWLOTSKY JM
MARCELLIN P
PERRILLO R
Citation: Da. Marshall et al., ECONOMIC-ANALYSIS OF VIRAL LOAD TESTING AT 3 MONTHS TO GUIDE TREATMENT DECISIONS FOR PATIENTS WITH CHRONIC HEPATITIS-C (HCV), Hepatology, 28(4), 1998, pp. 1716-1716
Citation: Cp. Mclaughlin et Kn. Simpson, THE NEW REALITIES IN HEALTH-CARE TECHNOLOGY-ASSESSMENT IN US INSTITUTIONS, International journal of technology management, 15(3-5), 1998, pp. 507-521
Citation: Kn. Simpson et al., IDIOPATHIC THROMBOCYTOPENIA PURPURA - TREATMENT PATTERNS AND AN ANALYSIS OF COST ASSOCIATED WITH INTRAVENOUS IMMUNOGLOBULIN AND ANTI-D THERAPY, Seminars in hematology, 35(1), 1998, pp. 58-64
Citation: Jf. Helm et al., ROLE OF SIGMOIDOSCOPY AND FECAL OCCULT BLOOD TESTING (FOBT) IN SCREENING FOR COLORECTAL-CANCER (CRC), Gastroenterology, 114(4), 1998, pp. 71-71
Authors:
CHANCELLOR JV
HILL AM
SABIN CA
SIMPSON KN
YOULE M
Citation: Jv. Chancellor et al., MODELING THE COST-EFFECTIVENESS OF LAMIVUDINE ZIDOVUDINE COMBINATION THERAPY IN HIV-INFECTION/, PharmacoEconomics, 12(1), 1997, pp. 54-66
Citation: Mc. Portela et Kn. Simpson, MARKERS, COFACTORS AND STAGING SYSTEMS IN THE STUDY OF HIV DISEASE PROGRESSION - A REVIEW, Memorias do Instituto Oswaldo Cruz, 92(4), 1997, pp. 437-457
Citation: Jf. Helm et al., SCREENING FOR COLORECTAL-CANCER (CRC) BY FECAL OCCULT BLOOD TESTING (FOBT) IS COST-EFFECTIVE, BUT IS IT AFFORDABLE, Gastroenterology, 112(4), 1997, pp. 18-18
Citation: Jf. Helm et al., WHAT DO WE GAIN BY SCREENING FOR COLORECTAL-CANCER (CRC) WITH 6 TESTSFOR FECAL OCCULT BLOOD, AND AT WHAT COST, Gastroenterology, 112(4), 1997, pp. 576-576
Authors:
SHUGARS DA
BENSON K
WHITE RP
SIMPSON KN
BADER JD
Citation: Da. Shugars et al., DEVELOPING A MEASURE OF PATIENT PERCEPTIONS OF SHORT-TERM OUTCOMES OF3RD MOLAR SURGERY, Journal of oral and maxillofacial surgery, 54(12), 1996, pp. 1402-1408
Authors:
CHANCELLOR JVM
HILL AM
SABIN CA
SIMPSON KN
YOULE M
Citation: Jvm. Chancellor et al., MODELING THE COST-EFFECTIVENESS OF EPIVIR(TM) (3TC(TM)) RETROVIR(TM) (ZIDOVUDINE) COMBINATION THERAPY IN HIV-INFECTION, AIDS, 10, 1996, pp. 23-23
Citation: Kn. Simpson et Rl. Lavallee, ANTIRETROVIRAL DRUG COST OFFSETS IN 7 DEVELOPED-COUNTRIES - SAQUINAVIR, ZALCITABINE, AND ZIDOVUDINE, AIDS, 10, 1996, pp. 66-66
Citation: Mw. Russo et al., WEIGHING THE BENEFITS AND RISKS OF LOW-DOSE ASPIRIN IN PRIMARY PREVENTION OF COLORECTAL-CANCER (CRC), Gastroenterology, 110(4), 1996, pp. 36-36
Citation: Kn. Simpson, COST-EFFECTIVENESS AND AIDS - SCIENCE OR MARKETING - PROCEEDINGS OF AWORKSHOP HELD IN WASHINGTON, DC, JANUARY 28, 1995 - INTRODUCTION, Journal of acquired immune deficiency syndromes and human retrovirology, 10, 1995, pp. 5-5
Citation: Kn. Simpson, DESIGN AND ASSESSMENT OF COST-EFFECTIVENESS STUDIES IN AIDS POPULATIONS, Journal of acquired immune deficiency syndromes and human retrovirology, 10, 1995, pp. 28-32
Citation: Da. Revicki et al., EVALUATING THE QUALITY-OF-LIFE ASSOCIATED WITH RIFABUTIN PROPHYLAXIS FOR MYCOBACTERIUM-AVIUM COMPLEX IN PERSONS WITH AIDS - COMBINING Q-TWIST AND MULTIATTRIBUTE UTILITY TECHNIQUES, Quality of life research, 4(4), 1995, pp. 309-318
Authors:
GILSTRAP LC
CHRISTENSEN R
CLEWELL WH
DALTON ME
DAVIDSON EC
ESCOBEDO MB
GJERDINGEN DK
GODDARDFINEGOLD J
GOLDENBERG RK
GRIMES DA
HANSEN TN
KAUFFMAN RE
KEELER EB
OH W
SUSMAN EJ
VOGEL MG
AVERY ME
BALLARD PL
BALLARD RA
CROWLEY P
GARITE T
GOLDENBERG RL
HANKINS GDV
JOBE AH
KOPPE JG
MAHER JE
MERKATZ IR
SHANKARAN S
SIMPSON KN
SINCLAIR JC
SLOTKIN TA
TAEUSCH HW
WRIGHT LL
ALEXANDER D
BERBERICH MA
BRACKEN M
COOPER L
CULPEPPER L
ELLIOTT JM
FERGUSON JH
FRIGOLETTO F
GAIL DB
HALL WH
JONES MD
MEDOFFCOOPER B
MERENSTEIN GB
WHALEN JM
Citation: Lc. Gilstrap et al., EFFECT OF CORTICOSTEROIDS FOR FETAL MATURATION ON PERINATAL OUTCOMES, JAMA, the journal of the American Medical Association, 273(5), 1995, pp. 413-418
Citation: Kn. Simpson et al., A MODEL FOR ESTIMATING THE IMPACT OF CHANGES IN CHILDRENS VACCINES, American journal of public health, 85(12), 1995, pp. 1666-1672
Citation: Kn. Simpson et Sr. Lynch, COST SAVINGS FROM THE USE OF ANTENATAL STEROIDS TO PREVENT RESPIRATORY-DISTRESS SYNDROME AND RELATED CONDITIONS IN PREMATURE-INFANTS, American journal of obstetrics and gynecology, 173(1), 1995, pp. 316-321
Citation: Da. Revicki et al., QUALITY-OF-LIFE IN RIFABUTIN PROPHYLAXIS FOR MYCOBACTERIUM-AVIUM COMPLEX IN PEOPLE WITH AIDS, Quality of life research, 3(1), 1994, pp. 44-44
Authors:
SMITH JA
CHODAK GW
SCARDINO PT
JOHANSSON JE
MILLER GJ
FUKS Z
OLSSON CA
ROMAS NA
WILT TJ
LITTRUP PJ
CATALONA WJ
ADOLFSSON J
WHITMORE WF
SIMPSON KN
ZIPPE CD
PAULSON DF
BRENDLER CB
Citation: Ja. Smith et al., DISCUSSION, The Journal of urology, 152(5), 1994, pp. 1769-1772
Citation: Kn. Simpson, PROBLEMS AND PERSPECTIVES ON THE USE OF DECISION-ANALYSIS MODELS FOR PROSTATE-CANCER, The Journal of urology, 152(5), 1994, pp. 1888-1893
Authors:
CATALONA WJ
COCKETT ATK
GOHAGAN JK
WILT TJ
LANGE PH
CHODAK GW
OLSSON CA
MCCULLOUGH DL
PROROCK PC
BAGSHAW MA
SCARDINO PT
ANDRIOLE GL
RAMSEY E
KLEIN EA
BARRY MJ
MENON M
SMITH AY
CORREA RJ
SIMPSON KN
GRAYHACK JT
DEKERNION JB
KOONTZ WW
FEIGHTNER JW
HEMSTREET GP
Citation: Wj. Catalona et al., DISCUSSION, The Journal of urology, 152(5), 1994, pp. 1915-1921